Idasanutlin is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Idasanutlin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Idasanutlin is under development for the treatment of advanced or metastatic solid tumors, and hematological tumors like advanced malignancy, , metastatic breast cancer, essential thrombocythemia, B-cell acute lymphocytic leukemia (b-cell acute lymphoblastic leukaemia), neuroblastoma. The drug candidate is administered orally. It is a new molecular entity (NME). The drug candidate is a second-generation inhibitor of MDM2. It was also under development for the treatment of polycythemia vera and acute myelogenous leukemia (AML).
It was under development for diffuse large B-cell lymhoma and follicular lymphoma.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Idasanutlin’s drug-specific PTSR and LoA scores, buy the report here.